Global data shows a sharp rise in adult ADHD diagnoses and medication prescriptions

Figures released in the Journal of Psychopharmacology reveal a substantial surge in both diagnoses and prescriptions for attention deficit hyperactivity disorder (ADHD) across multiple countries worldwide. The research, published on 8th August 2023, examined globally published studies on ADHD diagnoses and treatments. The analysis found that amongst the UK demographic between 2000 and 2018, a sharp rise in ADHD diagnoses and treatment prescriptions occurred in all age groups.

The most notable increase was seen in children; however, the data also pointed towards a significant rise in adults. For instance, men aged between 18-29 experienced an approximately 20-fold increase in diagnoses, alongside an almost 50-fold increase in prescriptions. The sex ratio of ADHD diagnoses in childhood and adolescence was about 4:1 male to female, but this ratio nearly equalized in adulthood.

The increase in ADHD diagnoses might be linked to heightened recognition of how ADHD manifests in girls and adults, groups that have historically been underdiagnosed. Simultaneously, there has been a marked increase in prescriptions for ADHD treatments. In England, for example, prescriptions of central nervous system stimulants, the primary ADHD treatments, saw a 32% rise in adults over 18 in 2021-22.

This was the first time since records began in 2015 that more adults were prescribed these drugs than children. A study covering over 154 million people across 13 countries in North America, Europe, and Asia also showed a similar trend in ADHD medication prescriptions.

Several factors appear to explain this surge in both ADHD diagnoses and prescriptions. These include heightened public awareness, improved doctors' understanding of symptom variations, and the availability of new and improved medications. Furthermore, the disorder's manifestation is now recognized more accurately in groups who were previously overlooked due to their atypical symptom presentation.

This includes women and girls, and people displaying predominantly inattentive symptoms. However, these explanations might not fully account for the phenomenon. The review also highlighted other possible contributing factors, such as debates over potential issues of overdiagnosis and over-prescription. Some experts argue there may not be evidence to support widespread overdiagnosis in the UK.

The rising rates of ADHD diagnoses and prescriptions are, therefore, a multifaceted issue that warrants further examination beyond apparent explanations, considering cultural, economic, social, and technological pressures in a globally competitive environment.